Navigation Links
PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDS's Marketplace 2012 Trade Convention
Date:6/12/2012

SCHOFIELD, Wis., June 12, 2012 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS) announced today that they will be attending NACDS's tradeshow, Marketplace 2012, being held in Denver, Colorado between June 23- 26, 2012.

In conjunction with the event, PuraMed BioScience is implementing a media blitz for LipiGesic® M, which has been clinically tested by leading US headache specialists and found to be a safe, highly effective, first-line therapy for treating migraine pain and its associated symptoms.

Attendance at the annual NACDS conference, will give PuraMed BioScience the opportunity to introduce LipiGesic M to over 230 retail companies that represent over 145,000 retail outlets. "We have already scheduled over 30 appointments with key wholesalers and retailers from all across the company," said Russ Mitchell, president and CEO of PuraMed BioScience.

"Now that we have established national distribution with our main retail partners, it is time to expand our distribution," said Mitchell. "The NACDS Marketplace 2012 is the best place to begin this process. There is no other trade event where we can get our clinically-tested Migraine treatment product in front of this many distribution opportunities at one time."

Coinciding with the NACDS Marketplace 2012 tradeshow, PuraMed BioScience has planned and is executing its most extensive advertising campaign to date.

The marketing blitz was developed to introduce consumers in the Denver region to the benefits, effectiveness and availability of clinically-tested LipiGesic M.

The eight-week media push, which will include newspaper, radio, television and in-store video displays, will begin in Denver, Colorado, but will also include areas around the region such as Colorado Springs, Cheyenne, Wyoming, and Albuquerque, New Mexico.

"We are testing this type of 'media-blitz' advertising in the Denver region to see if it can be then be used as a model to carry forward into other urban centers across the US," said Mitchell. "We have been working with our retail partner and have devoted resources to help them educate their pharmacists and their consumers about LipiGesic M."

The main message of the advertising campaign will be the effectiveness, speed and unique delivery system of LipiGesic M. Messages will use real-life testimonials and presentations by medical spokespersons to inform the public about the product.

LipiGesic M is a natural, homeopathic, gel that is administered sublingually (under the tongue). Best results are achieved when LipiGesic M is administered according to directions and migraine suffers do not eat or drink for 15 minutes after taking LipiGesic M.

Users often report that LipiGesic M relieves their migraine in minutes.

The clinical trial results published in the July 2011 issue of Headache: The Journal of Head and Face Pain, a top-tier medical publication, shows that LipiGesic M is an effective, first-line treatment for migraine when used at the first sign of headache. LipiGesic M has no known drug interactions, has an excellent safety profile, and does not produce rebound headache.

To promote LipiGesic M to the medical community, PuraMed BioScience has already sent sample kits to over 120 health professionals in the Denver region who have requested samples of LipiGesic M.

 "We timed this incentive to coincide with the NACDS convention so that if any attendees should visit stores in the region, they would see how our existing retail partners market our product," said Mitchell.

To learn more about the NACDS trade event, go to: http://www.nacdsmarketplace.org/

To learn more about this homeopathic migraine product and read the clinical study, visit www.LipiGesic.com.

About the Company:PuraMed BioScience, Inc., engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic® M, which provides acute relief from migraine headaches; the company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. 

For more information on PuraMed BioScience, visit www.PuraMedBioScience.com, join the company's group page on Facebook by searching "PuraMed BioScience" and follow the company on Twitter at www.twitter.com/puramed.

Forward-Looking Statements:This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.CONTACT:Russell Mitchell, Chairman and CEOPuraMed BioScience, Inc.715-359-6373rmitchell@PuramedBioScience.comWebsite: www.lipigesic.com


'/>"/>

SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. NineSigma Launches NineSights, the Worlds First Open Innovation Social Media Destination for Innovation Seekers and Solution Providers
2. MindSpec launches online Autism Reading Room
3. Wiley-Blackwell launches new open-access journal: Food Science & Nutrition
4. WanderID Launches Breakthrough ID Product for Children, Seniors
5. Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes
6. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
7. Elsevier launches new journal Algal Research
8. LABS, Inc. Launches Suite of Next-Generation Test Offerings; Focuses on Expanding Complex Biologic Testing Portfolio in 2012
9. Technology eases migraine pain in the deep brain
10. Suspicion resides in 2 regions of the brain
11. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/14/2016)... HANOVER , Allemagne, March 14, 2016 /PRNewswire/ ... http://www.apimages.com ) - --> - ... ) - --> ... les solutions biométriques, fournit de nouveaux lecteurs d,empreintes ... lecteur LF10 de DERMALOG sera utilisé pour produire ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... , ... April 27, 2016 , ... ... is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  ... Director and one of the founding commercial leaders responsible for the commercialization of ...
(Date:4/27/2016)... ... 2016 , ... PathSensors, Inc., a leading environmental testing company, ... assist PathSensors in expanding the use of the company’s CANARY® technology in the ... for the detection of harmful pathogens, including a number of bacteria, viruses, toxins, ...
(Date:4/27/2016)... ... 2016 , ... Global Stem Cells Group CEO Benito Novas announced ... of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. ... for hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on ... of Catherine Moukheibir as Chairman of its Board of Directors. ... Jacques Garaud , who contributed to the rapid development of ... Catherine started her career in strategy consulting and investment ... London .  She held C-Suite level roles in some ...
Breaking Biology Technology: